ライフサイエンスコーパス: beta-gal

1 beta-gal cDNA-transduced keratinocytes did not demonstra

2 beta-gal staining in all lines followed a similar patter

3 beta-gal+ cells in TIE2-LacZ vessels grafted to Balb/c m

4 beta-gal-positive cells expressing mesenchymal markers a

5 Interestingly, 35+/-19% beta-gal+ cells were found in arterial segments allograf

6 C57BL/6 mice that rejected congenic C57BL/6 beta-gal transgenic skin were tested in enzyme-linked im

7 se DOME homo-dimerisation, we have applied a beta-gal complementation technique that allows the detec

8 Using this substrate, we developed a beta-gal activity assay method.

9 row cells, a proportion of cells displayed a beta-gal+ staining.

10 ells of microvessels within allografts had a beta-gal+ staining in the media at 1 week and in the neo

11 and p75, on intact mammalian cells, using a beta-gal protein-protein interaction system.

12 In nucleus accumbens, beta-gal was expressed in several major subpopulations o

13 ical markers of senescence, including acidic beta-gal staining, induction of p16INK4a, and p15INK4b e

14 a significant increase of mature and active beta-gal and its C-terminal fragment.

15 showed intracellular accumulation of active beta-gal.

16 adenovirus expressing beta-galactosidase (Ad-beta gal)-transfected macrophages and produced elevated

17 r LEW kidneys were perfused with Ad-HO-1, Ad-beta-gal, or PBS, stored at 4 degrees C for 24 h, and tr

18 e groups [group 1: no treatment, group 2: Ad-beta-gal, group 3: AdvIL-10, group 4: CsA (10 mg/kg), an

19 tio at day 7 was elevated in both PBS and Ad-beta-gal, as compared with the Ad-HO-1 group (12.0 and 9

20 val advantage when compared with PBS- and Ad-beta-gal-treated controls, with median survival of 100,

21 ovirus that expresses beta-galactosidase (Ad-beta-gal) was used.

22 vIL-10 (Ad-vIL-10) or beta-galactosidase (Ad-beta-gal) were derived from adenovirus type 5.

23 and glomerulosclerosis was more severe in Ad-beta-gal group at all time points.

24 val of liver grafts increased from 50% in Ad-beta-gal untreated controls to 100% after Ad-IL-13 gene

25 red either adenovirus Ang-1 (Ad-Ang-1) or Ad-beta-gal systemically immediately after ligation of the

26 Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p

27 plant in the Ad-HO-1 group, compared with Ad-beta-gal controls (P < 0.05); tubular HO-1 expression wa

28 as 16 +/- 5 episodes per h (n = 6) in the Ad.beta gal group, 22 +/- 6 in the Ad.PV group, and 4 +/- 2

29 coding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

30 Ad.Kv4.3) or the beta-galactosidase gene (Ad.beta-gal).

31 eatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanc

32 ely (P<0.05) in AS myocytes infected with Ad.beta-gal compared with sham myocytes.

33 AS rats infected with Ad.beta-gal developed cardiac hypertrophy compared with sha

34 y density compared with pigs treated with Ad.beta-gal was found at 3 months and suggests an angiogeni

35 ed by 4.2% (P=0.004) in pigs treated with Ad.beta-gal.

36 odified fiber protein and infection with Ad5.beta gal.Delta F, an E1-, E3-, and fiber-deleted adenovi

37 nsgenes for either beta-galactosidase (adeno-beta-gal, n=11) or the human beta(2)-adrenergic receptor

38 ene expression among animals receiving adeno-beta-gal.

39 DTH response and proliferation assays after beta-gal immunization.

40 All beta-gal-positive cells exhibited abundant cytoplasm, a

41 ve cells within injured lungs was nearly all beta-gal-positive, indicating epithelial cells as the ma

42 vel, in the central nucleus of the amygdala, beta-gal was found in cells both with and without mu opi

43 binding inhibited receptor dimerization and beta-gal complementation.

44 th methylprednisolone and antibodies, EA and beta-gal were detected, and replicating virus was recove

45 not differ between the FGF-2-fibroblast and beta-gal-fibroblast groups.

46 roblasts, we implanted FGF-2-fibroblasts and beta-gal-fibroblast into the striatum of rats but did no

47 nd isolated cells were evaluated for GFP and beta-gal as well as expression of alpha-smooth muscle ac

48 from untreated liver expressed both GFP and beta-gal with a fibroblast-like morphological change but

49 s never showed double-positivity for GFP and beta-gal.

50 the pattern of X-gal staining in the OE and beta-gal-ir axons in the OB closely resembled that of un

51 -associated heterochromatic foci (SAHF), and beta-gal staining.

52 ssessed the retinal location of ANT and ANT1-beta-gal reporter protein, mitochondrial activity with c

53 rocessing and presentation using an antigen (beta-gal) that was either applied to or expressed in RPE

54 chimeric receptor dimerization detectable as beta-gal enzymatic activity.

55 ted open reading frames (ORFs) translated as beta-gal chimeras are selected as a candidate pool of po

56 ding growth arrest and senescence-associated beta-gal (SA-beta-gal) activity.

57 active AMPK increased senescence-associated beta-gal activity, whereas infection with an adenovirus

58 egative AMPK decreased senescence-associated beta-gal activity.

59 al tolerance was assessed by placement of B6 beta-gal transgenic (tg) and third-party skin grafts.

60 y prevented the induction of tolerance to B6 beta-gal tg skin grafts.

61 in chimeric mice expressing GFP or bacterial beta-gal or harboring the male Y chromosome exclusively

62 innocuous or self-specific knocked in BCRs, beta-gal was preferentially expressed in pre-B cells fro

63 ic factor (BDNF)LacZ mice reveals that BDNF (beta-gal) and trkB colocalize, mainly in type III taste

64 f, reveal an unambiguous correlation between beta-gal activity and the solubility/folding of the targ

65 d a marked increase in cells expressing both beta-gal, indicating bone marrow origin and Tie-2 expres

66 were >100-fold higher than those afforded by beta-gal- B cells following adoptive transfer to naive h

67 in awake, alert animals were not altered by beta-gal or wtGi.

68 actoside conjugate, must first be cleaved by beta-gal before it can be catalyzed by firefly luciferas

69 galactopyranoside (DDAOG), can be cleaved by beta-gal to produce 7-hydroxy-9H(I,3-dichloro-9,9-dimeth

70 d to the inhibitory molecule daunorubicin by beta-gal.

71 t loss of endothelial cells was evidenced by beta-gal staining for vein grafts in transgenic mice exp

72 pyranoside (OFPNPG) is readily hydrolyzed by beta-gal with a corresponding decrease in the 19F-NMR si

73 yte-derived cells are permanently labeled by beta-gal and type I collagen-expressing cells are labele

74 ic manipulation primed a population of CD4+, beta-gal-specific, TGFbeta-producing T cells.

75 ease in the number of double-positive cells (beta-gal, isolectin B4) on the luminal surface in caroti

76 din-2-one) (DDAO), is not only a chromogenic beta-gal substrate but that the cleavage product has far

77 Using chromogenic beta-gal substrates, HCMV was detected during MK differe

78 Akt gene, or with the control vector Ad.CMV-beta-gal, which expresses beta-galactosidase.

79 Using this technology, constitutive beta-gal activity in engineered cells and inducible tiss

80 Conversely, beta-gal+ cells were observed on the surface of vein seg

81 sistent with our model of opiate dependence, beta-gal expression increased in the LC, but decreased i

82 pe controls, which coincided with diminished beta-gal+ endothelial cells on the surface of vein graft

83 In contrast, LECs do not present endogenous beta-gal in the context of MHC-II molecules to beta-gal-

84 Mice that express beta-gal in the retina and various control mice were imm

85 some tubular cells also appeared to express beta-gal as assessed by X-gal staining, but following su

86 of twelve founder mice were found to express beta-gal in podocytes (33% penetrance).

87 pproximately 20% of secondary AFCs expressed beta-gal.

88 of twlve NPHS2 mouse founder lines expressed beta-gal exclusively in podocytes (100% penetrance).

89 VTA and DRN the majority of cells expressing beta-gal were nonmonoaminergic.

90 that were previously made tolerant to female beta-gal tg skin were rapidly rejected, however, suggest

91 ssion and generated a fusion protein (FGF14N-beta-gal) containing the first exon of FGF14 and beta-ga

92 Strikingly, the FGF14N-beta-gal chimeric protein was efficiently transported in

93 g mice producing CD4(+) T cells specific for beta gal (beta galTCR).

94 s did not occur in mice double deficient for beta-gal and ganglioside synthase, beta-gal-/-/GalNAcT-/

95 of the P2 OR subtype via immunostaining for beta-gal and concurrent OMP or GAP-43 expression in P2-I

96 ne week after the lesion, immunostaining for beta-gal and olfactory marker protein was virtually elim

97 of RPE with resting CD8 T cells specific for beta-gal.

98 ion experiments showed that the newly formed beta-gal(+) SMC were not derived from circulating bone m

99 Furthermore, beta-gal expression demonstrates a lineage relationship

100 c (Tg) for expression of beta-galactosidase (beta gal) on the retinal photoreceptor cell arrestin pro

101 A2a or the reporter gene beta-galactosidase (beta gal) or parvalbumin (PV), as early as 48 h before a

102 sion of genes coding for beta galactosidase (beta-gal), enhanced green fluorescent protein (EGFP), va

103 ly engineered to produce beta-galactosidase (beta-gal) (n=8) or FGF-2 (n=8), at two sites in the righ

104 of senescence-associated beta-galactosidase (beta-gal) activity and increased p16INK4a expression.

105 expression by assessing beta-galactosidase (beta-gal) activity in vivo.

106 ed the ability to detect beta-galactosidase (beta-gal) activity on the basis of 19F NMR chemical shif

107 0.09-fold (n = 4) higher beta-galactosidase (beta-gal) activity than N. meningitidis 5'lst::lacZ fusi

108 for in vivo detection of beta-galactosidase (beta-gal) activity.

109 beta-galactosidase (beta-gal) and beta-glucuronidase (beta-glucur) are both

110 in transplant model with beta-galactosidase (beta-gal) as a minor transplantation Ag.

111 or an irrelevant protein beta-galactosidase (beta-gal) as the control, induced to undergo apoptosis,

112 into the procedure with beta-galactosidase (beta-gal) as the detection enzyme.

113 ruitment domain (ARC) or beta-galactosidase (beta-gal) cDNA into the pTAT-hemagglutinin bacterial exp

114 denovirus containing the beta-galactosidase (beta-gal) cDNA, triacylglycerols in the liver and plasma

115 deficiency of lysosomal beta-galactosidase (beta-gal) characterizes the neurodegenerative disease GM

116 to weakly complementing beta-galactosidase (beta-gal) deletion mutants were expressed in cells in cu

117 o HC-Ad vectors encoding beta-galactosidase (beta-gal) driven by a TetOn system containing the rtTAS(

118 for EMT, mice expressing beta-galactosidase (beta-gal) exclusively in lung epithelial cells were gene

119 ogenous Escherichia coli beta-galactosidase (beta-gal) expressed through a retinal arrestin promoter.

120 and cellular mapping of beta-galactosidase (beta-gal) expression during naltrexone-precipitated with

121 mice were generated and beta-galactosidase (beta-gal) expression was analyzed.

122 sion of an axon-targeted beta-galactosidase (beta-gal) from such vectors supports mapping specific co

123 used to release endemic beta-galactosidase (beta-gal) from the bound bacterial cells; (3) the releas

124 murine VEGF gene and the beta-galactosidase (beta-gal) gene from a retroviral promoter were implanted

125 n of HCMV containing the beta-galactosidase (beta-gal) gene.

126 beta-Galactosidase (beta-gal) has been widely used as a transgene reporter e

127 se animals, staining for beta-galactosidase (beta-gal) identifies cells in which NF-kappaB has been a

128 In these mice, beta-galactosidase (beta-gal) immunoreactivity is an indicator of cells that

129 lubilize heat-aggregated beta-galactosidase (beta-gal) in the absence of the Hsp70 system.

130 beta-Galactosidase (beta-gal) is commonly used as a reporter gene in biologi

131 We demonstrate that when beta-galactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T

132 nant adenovirus encoding beta-galactosidase (beta-gal) or alpha(s)* was applied to arterial segments

133 cells, which are either beta-galactosidase (beta-gal) positive or beta-gal negative.

134 g the SM22alpha promoter-beta-galactosidase (beta-gal) reporter transgene were crossed to apolipoprot

135 he M9PROM was fused to a beta-galactosidase (beta-gal) reporter.

136 t the enhancer showed no beta-galactosidase (beta-gal) staining whereas those harboring latent virus

137 roduced progeny in which beta-galactosidase (beta-gal) was permanently expressed in B cells of the GC

138 th adenoviruses encoding beta-galactosidase (beta-gal), activation-deficient Akt (AA-Akt), or constit

139 e expressing ROSA26 stop beta-galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) green flu

140 ith hen egg lysozyme and beta-galactosidase (beta-gal), demonstrating adaptive immune responses again

141 CMV promoter expressing beta-galactosidase (beta-gal), eNOS, SOD1, or vehicle.

142 novirus (rAd.A20) or rAd.beta-galactosidase (beta-gal), implanted, harvested 4 weeks after transplant

143 r early antigen (EA) and beta-galactosidase (beta-gal), respectively.

144 control group expressing beta-galactosidase (beta-gal), respectively.

145 th adenoviruses encoding beta-galactosidase (beta-gal), wild-type Galpha(i2) (wtGi), or constitutivel

146 challenged mice with the beta-galactosidase (beta-gal)-expressing tumor cells, C25.F6, vaccinated the

147 e, and the prevalence of beta-galactosidase (beta-gal)-positive cells was determined, indicative of C

148 blastocysts with p63+/+ beta-galactosidase (beta-gal)-positive ES cells, we show that secretory cell

149 lowed by the addition of beta-galactosidase (beta-gal)-specific CTLs.

150 lacZ operon encoding for beta-galactosidase (beta-gal).

151 deficiency of lysosomal beta-galactosidase (beta-gal).

152 and omega- fragments of beta-galactosidase (beta-gal).

153 ce were made tolerant to beta-galactosidase (beta-gal).

154 sses the omega-domain of beta-galactosidase (beta-gal).

155 duces protein fusions to beta-galactosidase (beta-gal); non-annotated open reading frames (ORFs) tran

156 Dlx2/tauLacZ [beta-galactosidase (beta-gal)]-expressing cells populate the central SVZ, wh

157 Lysosomal beta-D-galactosidase (beta-gal), the enzyme deficient in the autosomal recessi

158 n increased expression of beta-galactosidase(beta-gal) plasmid in rat brain tissue in comparison to t

159 TAT-HA-beta-gal was also transduced into cells in all regions o

160 Transduction of TAT-HA-beta-gal was detected by X-gal staining.

161 proteins, TAT-HA-beta-galactosidase (TAT-HA-beta-gal), TAT-HA-myocilin, and TAT-HA-myocilin-EGFP.

162 tor and/or upon boosting with a heterologous beta-gal-carrying virus.

163 nly if prepulsed with cognate peptide, or if beta-gal-expressing RPE was pretreated to induce upregul

164 The ability to image beta-gal expression in living animals would further exte

165 long with beta-galactosidase-immunoreactive (beta-gal-ir) axonal processes in the OB after short (1 w

166 In beta-gal chimeras, some tubular cells also appeared to e

167 in endogenous protein and mRNA levels and in beta-gal activity.

168 d that IRF4 transcripts were up-regulated in beta-gal(+) pre-B cells.

169 ol place conditioning, we observed increased beta-gal staining in the nucleus accumbens (NAC) shell a

170 bone marrow transplantation showed increased beta-gal activity in different brain regions and reduced

171 In addition, withdrawal increased beta-gal expression in the continuum of the extended amy

172 The endogenous and phage-induced beta-gal was detected using the electrochemical method w

173 l as bone marrow macrophages, showed intense beta-gal histo- or cytostaining in adult noggin+/- mice

174 Interestingly, beta-gal+ cells were evenly distributed on the surface o

175 (2) release of the endogenous intracellular beta-gal from E. coli following infection.

176 IkappaB alpha gene was replaced with a lacZ (beta-gal) reporter complementary DNA (cDNA; IkappaB alph

177 In LC, beta-gal expression was induced predominantly in tyrosin

178 lactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells undergo deletion via the P

179 ypomorphic mice expressing a promoter-linked beta-gal reporter to show that inflammatory colitis supp

180 hicken gamma globulin showed that long-lived beta-gal+ B cells exclusively contained somatically muta

181 We cloned VLRB binders of lysozyme, beta-gal, cholera toxin subunit B, R-phycoerythrin, and

182 Second male beta-gal tg grafts placed onto female recipients that we

183 lowing suppression of endogenous (mammalian) beta-gal, no tubular cells could be found that stained w

184 In the tongues of adult BDNF(LacZ) mice, beta-gal (BDNF) is present in long slender taste cells,

185 aracterized by a large flat cell morphology, beta-gal staining and irreversible loss of regenerative

186 Application of alpha(s)*, but not beta-gal containing adenovirus, inhibited formation of n

187 R T cells in mice with retinal expression of beta gal and inhibited the ear-swelling assay for delaye

188 go senescence as indicated by the absence of beta-gal activity and p16(INK4a) tumor suppressor expres

189 A substantial advantage of beta-gal as a bioluminescent probe is that the enzyme re

190 the properties of FLuc to the advantages of beta-gal permits bioluminescent imaging applications tha

191 The RF scar area and the area of beta-gal staining were measured and normalized to LV are

192 ndicated that in vivo real-time detection of beta-gal activity is possible by fluorescence imaging te

193 t vessels displayed a unique distribution of beta-gal+ cells on the surface at 3 days, 1 week, and 4

194 h level of expression of the omega-domain of beta-gal in the model K12 strains allowed us to detect,

195 r the N-terminal or the C-terminal domain of beta-gal resulted in the synthesis of correctly sized po

196 response increased with increasing doses of beta-gal-carrying vector and/or upon boosting with a het

197 lt of this complementation-an active form of beta-gal-was detected colorimetrically, and the high lev

198 Intravenous injection of beta-gal induced true immunologic tolerance to beta-gal

199 and underlying media showed complete loss of beta-gal activity in advanced atherosclerotic lesions.

200 The majority of beta-gal+ cells present in the allografts exhibited fibr

201 otid artery of wild-type mice, the number of beta-gal+ cells were reduced at 3 days and disappeared c

202 evealed a 2.9-fold increase in the number of beta-gal-positive cells per square millimeter appearing

203 the ability to trigger the overexpression of beta-gal during the infection of E. coli.

204 etection of E. coli by (1) overexpression of beta-gal in E. coli during the specific infection and (2

205 neurospheres recapitulated the phenotype of beta-gal-/- cells and activated this pathway by depletin

206 hanges from yellow to red in the presence of beta-gal.

207 pulmonary PW1(+) cells and the proportion of beta-gal(+) vascular SMC were increased, indicating a re

208 he bound bacterial cells; (3) the release of beta-gal was detected using chlorophenol red-beta-d-gala

209 Our results suggest that the C terminus of beta-gal is an essential domain of the catalytically act

210 Treatment of beta-gal-infected endothelial cells with an inhibitor of

211 eporter assay system for the wide variety of beta-gal systems currently in use.

212 As a result, luminescence is dependent on beta-gal activity.

213 adenovirus encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area

214 ure was found, which showed beta-gal/CD31 or beta-gal/von Willebrand factor double positivity.

215 cence with antibodies against GFP, DsRed, or beta-gal using the method of immunolabeling-enabled thre

216 the groups that received a burr hole only or beta-gal-fibroblasts at weeks 2 and 3 following lesionin

217 er beta-galactosidase (beta-gal) positive or beta-gal negative.

218 unchanged after gene transfection of SOD1 or beta-gal in arteries from diabetic or normal rabbits.

219 sites of diverse enzymes from the peptidase, beta-gal, and nucleotide synthase families.

220 ccessful implantation of myoblasts (positive beta-gal reaction product) in 6 of 6 surviving experimen

221 on to beta-gal96-103 significantly prolonged beta-gal transgenic skin graft survival, confirming its

222 prevented the decrease in SM22alpha promoter-beta-gal reporter transgene expression, including in cel

223 myosin heavy chain, or a SM22alpha promoter-beta-gal reporter, we collected arteries 7 and 14 days a

224 LacZ gene expression of the protein beta-gal was demonstrated as early as 1 hour, with expre

225 llowing isolation, using R26R-EYFP and R26R (beta-gal) reporter mice, respectively.

226 levels in nontransduced, and rAd.A20 or rAd.beta-gal-transduced human SMC cultures after cytokine tr

227 lt, antibodies conjugated to the recombinant beta-gal enzyme can be used to detect endogenous cells a

228 After 3 weeks of recovery, beta-gal-containing axons appeared to target many of the

229 t mice expressing a cardiomyocyte-restricted beta-gal reporter gene.

230 of CD25(-) beta galTCR T cells into retinal beta gal Tg mice on the Rag(-/-) background led to regul

231 y CD3(+)4(+)25(+) T cells from naive retinal beta gal(+) donors.

232 Endogenous retinal beta-gal expression depressed the DTH response and proli

233 Senescence-associated beta-galactosidase (SA beta-gal) activity was observed in lymphomas from Emu-my

234 senescence-associated beta-galactosidase (SA beta-gal) activity, apparently irreparable genomic DNA b

235 p16(Ink4a), p21, senescence-associated (SA) beta-gal activity, and SA secretion of proinflammatory c

236 rs of cellular senescence, p16(Ink4a) and SA-beta-gal.

237 ed bone marrow progenitor cells expressed SA-beta-gal and senescence-associated proteins p53 and p21(

238 is and senescence, tested as staining for SA-beta-gal, also expressed p16(INK4A).

239 escence induction, tested as staining for SA-beta-gal, in reoxygenated progenitor cells was closely c

240 rrest and senescence-associated beta-gal (SA-beta-gal) activity.

241 senescence-associated beta-galactosidase (SA-beta-gal) activity and production of intracellular react

242 senescence-associated beta-galactosidase (SA-beta-gal) activity but an increase in adenosine triphosp

243 en species (iROS), SA-beta-galactosidase (SA-beta-gal) activity, and autofluorescence (AF) was assess

244 ameter) anti-PECAM/SA-beta galactosidase (SA-beta-gal) conjugates bound selectively to PECAM-expressi

245 ed as staining for SA-beta-galactosidase (SA-beta-gal), of bone marrow progenitor cells.

246 senescence-associated beta-galactosidase (SA-beta-gal).

247 With age, NSCs exhibited increased SA-beta-gal activity and decreased proliferation and pool s

248 ditions and significantly decreased iROS, SA-beta-gal, and AF normally induced by hyperoxic condition

249 enhanced expression of senescent markers SA-beta-gal, PML, and p16(INK4a).

250 over, inhibition of ATM signaling reduced SA-beta-gal positivity but increased apoptosis of reoxygena

251 us containing the enhancer continued to show beta-gal staining for long periods, extending to at leas

252 llary-like structure was found, which showed beta-gal/CD31 or beta-gal/von Willebrand factor double p

253 Blue X-gal staining, signifying beta-gal activity resulting from transduction, was obser

254 xpression was also confirmed both by in situ beta-gal staining and quantitative enzymatic activity as

255 Sorted beta-gal(+) pre-B cells showed increased levels of vario

256 gineered cells and inducible tissue-specific beta-gal expression in transgenic mice can now be visual

257 senescence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression.

258 cient for beta-gal and ganglioside synthase, beta-gal-/-/GalNAcT-/-, which do not accumulate GM1.

259 t germ agglutinin (WGA) and an axon-targeted beta-gal supports mapping both specific projections of t

260 TAT-beta-gal and TAT-ARC readily transduced into perfused he

261 TAT-beta-gal and TAT-ARC were conjugated with Texas Red and

262 r to produce genetic in-frame TAT-ARC or TAT-beta-gal fusion proteins for use in cell culture and in

263 lt hearts were perfused with recombinant TAT-beta-gal or TAT-ARC (20 nmol/L) for 15 minutes and then

264 These results demonstrate that beta-gal complementation provides a rapid, simple, and s

265 t studies in chimeric mice demonstrated that beta-gal+ cells of microvessels in transplant arterioscl

266 polymerase chain reaction, it was found that beta-gal(+) cells were mainly expressing CD31 and CD144.

267 Specifically, we show that beta-gal-expressing 9L gliomas are readily detectable by

268 Our results suggest that beta-gal-expressing bone marrow (BM)-derived cells selec

269 Experiments that removed the beta gal(+) retina by enucleation showed that subsequent

270 The beta-gal catalyzed PAPG to an electroactive species p-am

271 The beta-gal/DDAOG assay method should provide a fluorescent

272 The beta-gal/DDAOG assay method was also tested in transient

273 An optimized buffer for the beta-gal/DDAOG assay was also formulated.

274 ) promoter (COL1A2) cloned upstream from the beta-gal reporter gene were injected with carbon tetrach

275 In the beta-gal group, cardiomyopathy worsened over time.

276 revealed a mild reduction in rotation in the beta-gal-fibroblast group compared to the burr hole only

277 peptides that spanned a 94-aa region of the beta-gal sequence.

278 eart transplant resulted in migration of the beta-gal+ cells into the lesions of chronic rejection in

279 same number of myoblasts expressing only the beta-gal gene.

280 Here, we show, using the beta-gal gene as a reporter, that amber, ochre, and opal

281 memory CD8+ T cells are contained within the beta-gal-marked CD8+ T cell population.

282 M9PROM activation was localized through beta-gal staining.

283 depressed development of immune responses to beta gal following systemic immunization with beta gal.

284 (19.6 vs. 12 days, P<0.001) when compared to beta-gal transfected controls.

285 rAAV5betagal intrastriatal injections led to beta-gal-positive parenchymal cells, but, unlike rAAV2be

286 ta-gal in the context of MHC-II molecules to beta-gal-specific CD4 T cells.

287 Provision of whole beta-gal, as opposed to beta-gal peptide, gave no evidence of T-cell activation.

288 cluding highly sensitive 19F NMR response to beta-gal activity (Deltadelta=9.0 approximately 9.4 ppm)

289 ta-gal induced true immunologic tolerance to beta-gal tg skin in wild-type but not in B-cell-deficien

290 Importantly, LECs transfer beta-gal to dendritic cells, which subsequently present

291 f total cells in the lesion-prone areas were beta-gal positive in apoE(-/-) with apoE(-/-)/TIE2-LacZ

292 Provision of whole beta-gal, as opposed to beta-gal peptide, gave no eviden

293 eta gal following systemic immunization with beta gal.

294 lurp1(-/-)) created by replacing exon 2 with beta-gal and neo cassettes.

295 MAPK staining in the intima as compared with beta-gal-treated vessels.

296 This polypeptide was found to copurify with beta-gal and protective protein/cathepsin A from mouse l

297 ondary AFCs showed a strong correlation with beta-gal expression, suggesting that nonmutated B cells

298 and various control mice were immunized with beta-gal and tested for immune responsiveness by the ear

299 ng tumor cells, C25.F6, vaccinated them with beta-gal-carrying viral vectors, and used quantitative R

300 ased cell migration in cells transduced with beta-gal, whereas AA-Akt blocked VEGF-induced cell locom